Obesity is a chronic disease of global public health concern, contributing to cardiovascular disease, type 2 diabetes and certain cancers. Currently approved anti-obesity drugs and surgery are expensive and not readily available in Nigeria.

Metformin, approved for type 2 diabetes, has been shown to promote weight loss among obese patients in high income countries. However, metformin's effects have not yet been demonstrated in Black African populations, which may have different genetic and environmental predispositions to obesity and to the effect of metformin. This blinded, placebo-controlled, randomized trial is determining the effect of metformin on weight loss, cardiovascular disease risk and insulin resistance in Black Nigerians.

Inclusion Criteria:

• • Obesity (defined as body mass index ≥ 30kg/m2),

  • Fasting plasma glucose (<7.0mmol/L)
  • No medical treatment for weight control in the previous 12 months
  • No participation in a current clinical trial

Exclusion Criteria:

• • Obesity (defined as body mass index ≥ 30kg/m2),

  • Fasting plasma glucose (<7.0mmol/L)
  • No medical treatment for weight control in the previous 12 months
  • No participation in a current clinical trial

Study protocol, statistical analysis plan, informed consent form, Non-identifiable patient measurements.

IPD will be made available after publishing of the research work likely from 1 Jan 2029 for 5 years (31 Dec 2033)

The research institution, the research funders, potential collaborators and funders.

Blinded Pharmacist